Evidence map›Paper›PMID 41607788›Full record

ReviewFrontiers in immunology2025

Tumor heterogeneity assessment using single-cell RNA sequencing (scRNA-seq): applications in lung cancer for diagnosis and treatment.

Cecilia Bica, Oana Zanoaga, Laura Pop, Cristina Ciocan, Lajos Raduly, Andreea Nuțu, Ioana Berindan-Neagoe, Andreas Bender

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cecilia BicaDepartment of Genomics, MEDFUTURE Institute for Biomedical Research, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Oana ZanoagaDepartment of Genomics, MEDFUTURE Institute for Biomedical Research, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Laura PopDepartment of Genomics, MEDFUTURE Institute for Biomedical Research, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Cristina CiocanDepartment of Genomics, MEDFUTURE Institute for Biomedical Research, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Lajos RadulyDepartment of Genomics, MEDFUTURE Institute for Biomedical Research, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Andreea NuțuDepartment of Genomics, MEDFUTURE Institute for Biomedical Research, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Ioana Berindan-NeagoeDepartment of Genomics, MEDFUTURE Institute for Biomedical Research, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Andreas BenderDepartment of Genomics, MEDFUTURE Institute for Biomedical Research, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent progress in single-cell RNA sequencing has led to mechanistic and clinically actionable insight into genetic heterogeneity and tumor progression

Indexed as

Carcinoma, Non-Small-Cell LungGenetic HeterogeneityLung NeoplasmsSequence Analysis, RNASingle-Cell AnalysisAnimalsBiomarkers, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansSingle-Cell Gene Expression AnalysisTumor MicroenvironmentBiomarkers, Tumorlung cancermolecular profilesingle-cell RNA sequencing (scRNA-seq)tumor heterogeneitytumor microenvironment (TME)

Identifiers

PMID41607788
PMCPMC12835674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.